
Pelage’s PP405 novel topical reawakens dormant follicle stem cells, showing signs of terminal regrowth and fueling late-stage alopecia research.
Christina Weng, MD, is the Chief Medical Officer at Pelage. She is also a board-certified dermatologist at Massachusetts General Hospital and on faculty at Harvard Medical School.

Pelage’s PP405 novel topical reawakens dormant follicle stem cells, showing signs of terminal regrowth and fueling late-stage alopecia research.